Randomized Trial of Adjuvant Tamoxifen in Node Negative Postmenopausal Breast Cancer
| Autor: | Nils Wilking, Anders Somell, Björn Cedermark, Ulrik Ringborg, Lars Erik Rutqvist, Ulla Glas, Hemming Johansson, Lambert Skoog, Sam Rotstein, Tolle Theve, Jutta Askergren, Marie-Louise Hjalmar |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Gynecology
Oncology medicine.medical_specialty business.industry medicine.drug_class Mammary gland Estrogen receptor Hematology General Medicine Antiestrogen medicine.disease law.invention medicine.anatomical_structure Breast cancer Randomized controlled trial law Estrogen Internal medicine medicine Radiology Nuclear Medicine and imaging business Estrogen Receptor Status Tamoxifen medicine.drug |
| Zdroj: | Acta Oncologica. 31:265-270 |
| ISSN: | 1651-226X 0284-186X |
| DOI: | 10.3109/02841869209088913 |
| Popis: | The paper presents long-term results of a randomized trial of adjuvant tamoxifen (40 mg daily for 2 or 5 years) versus surgery alone including 1 347 postmenopausal patients with histologically negative axillary nodes and a tumour diameter ≤ 30 mm. Data on the estrogen receptor status of the primary tumour were available in 1136 patients (84%). At a median follow-up of 7 years (range 1.7–13.0 years) there was a significant prolongation of the recurrence-free survival among those allocated to tamoxifen (p < 0.01), significantly fewer deaths due to breast cancer (p = 0.02) and a trend towards improved overall survival (p = 0.11). The treatment benefit was restricted to patients with ER-positive tumours. There was no significant reduction of breast cancer recurrences in the tamoxifen group among patients whose tumours were classified as ER-negative. The results support and extend previous studies in showing a long-term benefit of tamoxifen in postmenopausal breast cancer patients with node-negative, estrogen ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|